GlassScriptPhysician profile
Pablo M Lopez
NPI 1104081074
$6,369.06
in general payments reported to CMS, 2019-2025
26 companies · $2,919 in 2025
The $2,919 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $603 · 2024: $2,847 · 2025: $2,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,269 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,269.07 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,382.33 | 2023-2025 | |
| Janssen Biotech, INC. | $1,021.78 | 2023-2025 | Tremfya, Simponi Aria, Xarelto |
| Amgen INC. | $696.25 | 2023-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $682.95 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $394.39 | 2023-2025 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $344.06 | 2023-2025 | Acthar |
| Glaxosmithkline, LLC. | $316.11 | 2023-2025 | Benlysta |
| Pfizer INC. | $286.60 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $229.46 | 2024-2025 | Orencia |
| Genentech USA, INC. | $138.23 | 2024-2025 | Actemra, Gazyva |
| Fresenius Kabi USA, LLC | $125.20 | 2024-2025 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.67 | 2023-2024 | Ofev |
| Organon LLC | $112.90 | 2023-2024 | Hadlima, Renflexis |
| Sandoz INC. | $99.18 | 2023-2025 | Hyrimoz, Jubbonti |
| Alexion Pharmaceuticals, INC. | $57.65 | 2023-2024 | Strensiq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $55.61 | 2025 | Tymlos |
| Scilex Pharmaceuticals INC. | $45.22 | 2024 | |
| Novartis Pharmaceuticals Corporation | $43.69 | 2025 | |
| Fidia Pharma USA INC. | $41.18 | 2023-2025 | Hymovis, Triluron |
| Actelion Pharmaceuticals US, INC. | $39.40 | 2024-2025 | Opsumit, Uptravi |
| Ani Pharmaceuticals, INC. | $27.36 | 2025 | Purified Cortrophin Gel |
| Vertex Pharmaceuticals Incorporated | $25.47 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $23.96 | 2024 | Arcalyst |
| Aurinia Pharma U.S., INC. | $22.79 | 2025 | Lupkynis |
| Sobi, INC | $20.75 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $19.87 | 2024 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.